Cardiff Oncology (CRDF) Stock Price, Quote, News & History | Benzinga

Cardiff Oncology Inc (CRDF) Stock Price, Quote, News & History

CRDFNASDAQ

Trade with Public

Trade with Public

$0.9400

-0.0461-4.67%

At close: Aug 28, 5:00 PM EST

$0.9689

0.02893.07%

After Hours: Aug 28, 7:29 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$0.99

Close

$0.94

Volume / Avg.

528.70K / 1.42M

Day Range

$0.93 - $0.99

52 Wk Range

0.76 - 3.31

Market Cap

$75.38M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

49

Short Interest

15.61%

Days to Cover

15.27

Recent Cardiff Oncology, Inc. News

Crude Oil Moves Lower; US Producer Prices Fall 0.3% In June

Dow gains over 150 points, NASDAQ and S&P 500 also up. Consumer discretionary shares jump 1.2%, energy stocks fall 0.5%. Producer price index falls below expectations.

Avi Kapoor

Dow Gains Over 150 Points; Morgan Stanley Profit Tops Views

US stocks traded higher with Dow up 150 points. Consumer discretionary shares surged 1.3% while health care stocks fell 0.4%. Morgan Stanley beat earnings.

Avi Kapoor

This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.

Avi Kapoor

Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense

Cardiff Oncology sued Nerviano Medical Sciences over onvansertib licensing claims as analysts backed Cardiff's legal stance.

Vandana Singh

Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus

Cardiff Oncology shares fell 32% after a sudden CEO and CFO exit, trial strategy changes, and a negative analyst update that cut success odds and market potential.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-40.85M

Investing Cash Flow (TTM)

36.44M

Financing Cash Flow (TTM)

2.83M

Free Cash Flow (TTM)

-40.92M

Capital Expenditure (TTM)

-62.00K

Net Change in Cash (TTM)

-1.59M

Analyst Trends and Forecast

1

Jun

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$38.71M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

131.91

PB Ratio (TTM)

2.90

Earnings Yield % (TTM)

-60.67%

Earnings Yield % (FWD)

-64.72%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.34

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$9.20M

Debt to Equity

0.02

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$0.99

Close

$0.94

Volume / Avg.

528.70K / 1.42M

Day Range

$0.93 - $0.99

52 Wk Range

0.76 - 3.31

Market Cap

$75.38M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

49

Short Interest

15.61%

Days to Cover

15.27

About

Sector

Health Care

Industry

Biotechnology

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor curre...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Cardiff Oncology (CRDF) stock?

A

You can purchase shares of Cardiff Oncology (NASDAQ:CRDF) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Cardiff Oncology (CRDF) competitors?

A

Other companies in Cardiff Oncology’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Cardiff Oncology (CRDF) stock?

A

Cardiff Oncology has a consensus price target of $8.92.

Q

What is the current price for Cardiff Oncology (CRDF)?

A

The stock price for Cardiff Oncology (NASDAQ: CRDF) is $0.9689 last updated August 28, 2026 at 7:29 PM EDT.

Q

Does Cardiff Oncology (CRDF) pay a dividend?

A

There are no upcoming dividends for Cardiff Oncology.

Q

When is Cardiff Oncology (NASDAQ:CRDF) reporting earnings?

A

Cardiff Oncology does not have any upcoming earnings scheduled.

Q

Is Cardiff Oncology (CRDF) going to split?

A

There is no upcoming split for Cardiff Oncology.

Q

What sector and industry does Cardiff Oncology (CRDF) operate in?

A

Cardiff Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.